Wharton's jelly MSC & exosome protocols for cranial nerve inflammation & myelin support
Stem cell therapy for trigeminal neuralgia in Istanbul, Turkey
How our Istanbul medical team led by Uzm. Dr. Cihan Bolat reviews your cranial MRI and facial pain profile to design a targeted regenerative program.
Condition-specific editorial anatomy. Explanatory labels remain in accessible text.
Understanding the condition
Understanding the condition and our regenerative approach
Trigeminal neuralgia causes sudden, electric-shock-like paroxysms or persistent burning pain along the ophthalmic (V1), maxillary (V2), or mandibular (V3) branches of the fifth cranial nerve. Inside the trigeminal root entry zone and trigeminal ganglion, focal breakdown of the protective myelin sheath and chronic perineural inflammation cause light-touch sensory fibers to short-circuit (ephaptic cross-talk) into pain fibers, turning everyday actions like speaking, chewing, brushing teeth, or feeling a light breeze into exhausting triggers.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are investigated in trigeminal neuralgia for their ability to calm cranial neuroinflammation, stabilize hyperexcitable nerve membranes, and support myelin sheath repair. Through potent immunomodulatory and paracrine signaling, WJ-MSCs and nanoscale exosomes downregulate pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) within the trigeminal ganglion and brainstem nuclei while shifting reactive satellite glial cells and microglia toward a neuroprotective M2 phenotype. Simultaneously, their cargo of neurotrophic growth factors—including NGF, BDNF, and GDNF—and regenerative microRNAs supports Schwann cell and oligodendrocyte myelin homeostasis, protects axonal mitochondria from oxidative stress, and helps quiet abnormal sodium-channel firing along demyelinated trigeminal fibers.
At our Istanbul clinic led by Uzm. Dr. Cihan Bolat, we carefully review your high-resolution cranial nerve MRI, pain distribution, and medication history to design an individualized protocol combining systemic intravenous WJ-MSCs and exosomes, targeted intranasal exosome delivery along the trigeminal pathway, and intrathecal support when clinically indicated. Coordinated alongside your neurologist-prescribed medications, our program aims to reduce attack frequency and severity, soften trigger sensitivity, and restore comfortable eating, speaking, and sleep.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
Key biological processes and therapeutic targets
Trigeminal neuralgia is driven by focal demyelination at the nerve root transition zone, ephaptic cross-firing between tactile and nociceptive axons, satellite glial cell inflammation in the trigeminal ganglion, and central brainstem sensitization—mechanisms directly targeted by WJ-MSC and exosome therapy.
What our protocol aims to support
- Calming trigeminal & central neuroinflammation: Our WJ-MSC and exosome protocols aim to downregulate pro-inflammatory satellite glial and microglial cytokine signaling along the trigeminal pathway.
- Supporting myelin & Schwann cell trophic balance: Paracrine neurotrophic factors (NGF, BDNF, GDNF) and exosomal microRNAs aim to support the biological microenvironment required for nerve sheath maintenance and calmer axonal conduction.
- Promoting greater daily comfort & trigger resilience: By addressing neuro-immune hyperexcitability, the protocol aims to support reduced attack intensity and greater comfort during eating, speaking, and sleep.
- Coordinated with your neurologist's prescribed regimen: Your regenerative protocol in Istanbul is designed to run alongside your prescribed membrane-stabilizing medications and ongoing neurological care at home.
- 01
Focal demyelination & ephaptic nerve cross-talk
At the trigeminal root entry zone or along peripheral branches, vascular pulsatility or inflammatory demyelination strips away the insulating myelin sheath, allowing myelinated A-beta touch fibers to electrically cross-excite unmyelinated C-pain fibers. Wharton's jelly MSCs and exosomes deliver neurotrophic factors (BDNF, GDNF, NGF) and remyelination-supportive microRNAs that nourish Schwann cells and oligodendrocytes. By supporting the biological machinery responsible for myelin sheath maintenance and axonal insulation, regenerative signaling aims to reduce abnormal ephaptic short-circuiting. Better axonal insulation helps light touch feel like normal touch again rather than a pain trigger.
- 02
Perineural & trigeminal ganglion inflammation
Within the trigeminal (Gasserian) ganglion, activated satellite glial cells and infiltrating macrophages release TNF-α, IL-1β, and chemokines that upregulate voltage-gated sodium channels and keep trigeminal neurons in a state of hair-trigger hyperexcitability. WJ-MSCs and WJ-MSC exosomes release anti-inflammatory cytokines (IL-10, TGF-β) and regulatory vesicles that shift glial cells toward a calm, homeostatic phenotype. Downregulating local cytokine storms reduces inflammatory sensitization of trigeminal nociceptors. A quieter ganglion microenvironment supports fewer paroxysmal pain bursts.
- 03
Axonal & microvascular stress along cranial branches
Chronic mechanical pulsatility, prior viral injury, or dental/facial trauma impairs endoneurial microcirculation and creates oxidative mitochondrial stress along the V1, V2, and V3 branches. Nanoscale exosomes from Wharton's jelly MSCs transfer antioxidant enzymes, protective proteins, and angiogenic signals (VEGF) that support microvascular blood flow and buffer free-radical damage inside stressed axons. Improving cellular bioenergetics helps trigeminal nerve fibers maintain healthier resting membrane potentials. Stronger metabolic resilience protects axons against chronic degenerative aching.
- 04
Central brainstem pain-network sensitization
Months or years of intense trigeminal firing sensitize second-order neurons and microglia in the spinal trigeminal nucleus of the brainstem, creating a persistent background burning or throbbing ache even between sharp attacks. Exosomes delivered via intranasal-trigeminal and systemic routes—along with intrathecal WJ-MSCs when clinically indicated—reach central brainstem relays to calm microglial activation and support inhibitory neurotransmitter balance. Reducing central sensitization helps quiet continuous background facial pain and improves nighttime sleep comfort.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Repairing Myelin Insulation & Quieting Ephaptic Cross-Talk
In trigeminal neuralgia, loss of myelin insulation along the fifth cranial nerve allows harmless touch signals to jump directly onto adjacent pain-signaling axons like an uninsulated wire. At the same time, inflamed satellite glial cells inside the trigeminal ganglion bathe sensory neurons in excitatory cytokines that keep sodium channels hair-trigger sensitive. Regenerative biologics target both the neuro-inflammatory irritation and the trophic needs of myelin-producing Schwann cells and oligodendrocytes. Supporting nerve sheath integrity and calming glial inflammation aims to reduce spontaneous electric-shock firing.
Synergistic Systemic & Intranasal-Trigeminal Delivery
Wharton's jelly MSCs infused intravenously provide systemic immunomodulation, lowering circulating pro-inflammatory cytokines and supporting microvascular health around cranial nerves. Paired with concentrated WJ-MSC exosomes delivered both intravenously and intranasally, nanoscale vesicles engage the ophthalmic and maxillary trigeminal branches directly within the upper nasal mucosa to travel along the trigeminal nerve pathway toward the trigeminal ganglion and brainstem. These vesicles deliver NGF, BDNF, GDNF, and regulatory microRNAs that calm glial hyperexcitability and support myelin maintenance. Together, they address both peripheral trigeminal branches and central pain relays.
MRI-Guided Evaluation by Uzm. Dr. Cihan Bolat
Before recommending any protocol in Istanbul, our medical team reviews your high-resolution cranial MRI to evaluate neurovascular contact, secondary demyelinating lesions (such as multiple sclerosis), or post-herpetic/post-procedural nerve injury. Based on your exact trigeminal branch involvement (V1, V2, or V3) and clinical history, we customize your combination of intravenous, intranasal, and—when clinically indicated—intrathecal administration. Your prescribed membrane-stabilizing medications remain uninterrupted throughout your care.
Our treatment approach & administration routes
How our proposed Wharton's jelly MSC and exosome protocols work
- 01
Intravenous WJ-MSC Administration
Intravenous infusion delivers Wharton's jelly MSCs systemically to modulate circulating immune cells, reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and support microvascular endothelial health along cranial nerve pathways. By shifting systemic immune signaling toward regulatory T-cells and anti-inflammatory IL-10 production, intravenous WJ-MSCs help calm the peripheral inflammatory tone that feeds into the trigeminal ganglion. Systemic paracrine factors also nourish the vasa nervorum capillaries supplying the fifth cranial nerve. This provides a comprehensive systemic anti-inflammatory foundation for facial pain care.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 02
Intravenous WJ-MSC Exosome Administration
Intravenous WJ-MSC exosome infusion introduces billions of nanoscale extracellular vesicles carrying neurotrophic growth factors, anti-inflammatory proteins, and myelin-supportive microRNAs into the circulation. Because these lipid-bilayer vesicles cross the blood-nerve and blood-brain barriers, they reach both the trigeminal ganglion and central brainstem nuclei. Inside target neural and glial cells, exosomal cargo helps downregulate inflammatory sodium-channel sensitization and protect axonal mitochondria from oxidative stress. Pairing intravenous exosomes with WJ-MSCs delivers both rapid vesicular signaling and sustained cellular immunomodulation.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 03
Intranasal Exosome Administration
The nasal cavity is directly innervated by the ophthalmic (V1) and maxillary (V2) divisions of the trigeminal nerve, making intranasal administration a uniquely direct anatomical route for trigeminal neuralgia. When concentrated WJ-MSC exosomes are applied to the upper nasal mucosa, they interact with trigeminal nerve endings and are investigated for perineural and axonal transport directly toward the trigeminal ganglion and spinal trigeminal nucleus in the brainstem. While the exact percentage of intranasal exosomes reaching deep human central structures remains under clinical study, this painless, non-invasive route engages the trigeminal pathway at its anatomical gateway. Patients tolerate intranasal sessions comfortably without triggering facial pain flares.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
- 04
Intrathecal WJ-MSC Administration (When Clinically Indicated)
For selected patients—such as those with trigeminal neuralgia secondary to multiple sclerosis plaques, central brainstem demyelination, or severe refractory central sensitization—intrathecal WJ-MSC delivery into the cerebrospinal fluid may be included after specialist evaluation. Performed with or without sedation depending on clinical circumstances, intrathecal administration places cells directly into the CSF so neurotrophic factors (BDNF, GDNF) and anti-inflammatory cytokines can bathe the brainstem root entry zone and central trigeminal nuclei. Uzm. Dr. Cihan Bolat determines whether intrathecal support is appropriate based on your cranial MRI and clinical profile.
Role in your protocolOur medical team determines the exact Wharton's jelly MSC and exosome combination, dosage, and administration route after evaluating your medical history and reports.
What we aim to achieve
Therapeutic objectives and functional outcomes we track
Before treatment in Istanbul, our physicians establish your clinical baseline and define realistic biological and functional objectives to track during follow-up.
- 01
Daily Attack Frequency & Paroxysmal Severity
Tracking the number, duration, and electrical intensity of daily facial pain attacks. By calming satellite glial inflammation and supporting myelin insulation along trigeminal fibers, the protocol aims to reduce spontaneous firing and widen pain-free intervals.
- 02
Comfort During Eating, Speaking & Light Touch
Monitoring how comfortably you can chew, drink, speak, wash your face, or tolerate a breeze without triggering sharp flares. Reducing ephaptic cross-talk and peripheral nociceptor sensitivity aims to restore confidence in everyday facial movements.
- 03
Background Facial Calm & Sleep Continuity
Evaluating constant dull or burning background pain between attacks and how well you sleep through the night. Quieting central brainstem sensitization and oxidative axonal stress helps support calmer resting nerve tone.
- 04
Medication Stability & Daily Quality of Life
Following your overall daily comfort and whether your neurologist can maintain stable, tolerable doses of membrane-stabilizing medications over time. Biological support works alongside your medical regimen to improve day-to-day wellbeing.
How treatment is personalized
How our medical team evaluates your records and designs your protocol
How our Istanbul medical team led by Uzm. Dr. Cihan Bolat reviews your cranial MRI and facial pain profile to design a targeted regenerative program.
Medical history & reports we request
- Detailed facial pain distribution (V1, V2, or V3 branches), character, and triggers
- High-resolution cranial nerve MRI report evaluating vascular contact or secondary causes
- History of multiple sclerosis, herpes zoster, dental procedures, or prior nerve interventions
- Current membrane-stabilizing medications, dosages, and tolerability
- Individualized assessment by Uzm. Dr. Cihan Bolat to determine optimal administration routes
Clinical suitability & protocol checks
- Never stop or abruptly reduce prescribed anticonvulsant or facial pain medications (such as carbamazepine or oxcarbazepine) before or during travel.
- Our physicians review your cranial MRI in advance to ensure any structural lesion or severe neurovascular compression requiring neurosurgical consultation is identified.
- Your Istanbul visit is organized for maximum comfort, with gentle procedures and structured remote follow-up once you return home.
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
- 01
Contact us & share your medical reports
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
- 02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
- 03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
- 04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Transparent Istanbul pricing tailored to your protocol
After our medical team evaluates your records, we provide a written proposal explaining the recommended Wharton's jelly MSC and exosome preparations, administration routes, intended objectives, stay timeline, and itemized costs.
For 2026 planning context, targeted exosome and local orthopedic protocols typically range from $3,500–$6,500, while comprehensive Wharton's jelly MSC and exosome programs range from $7,000–$18,000. Your exact cost is confirmed after your medical evaluation.
- Never stop or abruptly reduce prescribed anticonvulsant or facial pain medications (such as carbamazepine or oxcarbazepine) before or during travel.
- Our physicians review your cranial MRI in advance to ensure any structural lesion or severe neurovascular compression requiring neurosurgical consultation is identified.
- Your Istanbul visit is organized for maximum comfort, with gentle procedures and structured remote follow-up once you return home.
What your written treatment proposal explains
- 01
Which Wharton's jelly MSC, exosome, or combined protocol is proposed for your condition?
- 02
Which administration routes are recommended and how do they work biologically?
- 03
What are the intended therapeutic objectives and expected stay length in Istanbul?
- 04
What is the itemized cost and how does 1, 3, and 6-month follow-up work after treatment?
Evidence & important considerations
Published clinical research and important considerations
Below is a summary of published human studies, investigated mechanisms, and important limitations relevant to regenerative medicine for this condition.
01 Systematic review of cellular therapies for trigeminal neuralgia
Open study- Product
- Mesenchymal stromal cells and neuro-regenerative cellular preparations
- Route
- Targeted perineural, intranasal-trigeminal, and systemic delivery models
- Study design
- Systematic review of preclinical models and early clinical observations in trigeminal neuropathic pain
- Finding
- Preclinical and early translational reports demonstrate anti-allodynic signaling, reduced neuroinflammation, and trophic myelin support across trigeminal pain models.
- Limitation
- Because large randomized human trials in trigeminal neuralgia are still needed, protocols are individualized after thorough MRI review and coordinated with standard neurological care.
Scientific references
Clinical studies and scientific references
FAQ
Frequently asked questions about this treatment
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.